US3733177A - Methods and compositions for the determination of uric acid in blood - Google Patents

Methods and compositions for the determination of uric acid in blood Download PDF

Info

Publication number
US3733177A
US3733177A US00214770A US3733177DA US3733177A US 3733177 A US3733177 A US 3733177A US 00214770 A US00214770 A US 00214770A US 3733177D A US3733177D A US 3733177DA US 3733177 A US3733177 A US 3733177A
Authority
US
United States
Prior art keywords
uric acid
reagent
acid
ions
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00214770A
Other languages
English (en)
Inventor
B Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of US3733177A publication Critical patent/US3733177A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y10T436/117497—Automated chemical analysis with a continuously flowing sample or carrier stream
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y10T436/117497—Automated chemical analysis with a continuously flowing sample or carrier stream
    • Y10T436/118339—Automated chemical analysis with a continuously flowing sample or carrier stream with formation of a segmented stream
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
    • Y10T436/148888—Uric acid

Definitions

  • Uric acid is normally present in some quantities in the fluids of mammals, particularly humans, as a result of normal body functions. In a given warm blooded animal, the uric acid content of body fluids must be held within carefully prescribed limits in order to preventundesirabl e consequences.
  • ingestion of certain purine-containing foods which normally have no effect on blood uric acid levels may unpredictably elevate uric acid blood levels.
  • the diagnostic compositions and methods of the present invention provide a reliable, convenient test for the quantitating of uric acid in the blood as well as affording a method whereby the quantitative determination may be carried out in a sequential or continuous flow system. Further, the diagnostic compositions and methods of the I present invention overcome many of the disadvantages of the prior art methods of determining uric acid in blood by not requiring a high degree of laboratory skill and technology, using a small specimen volume, and being highly accurate in the clinical situation.
  • a 5-(2-pyridyl)-2H- 1,4-benzodiazepine, or a water-soluble salt thereof, preferably in combination with a buffer is added with an aqueous solution of ferric chloride to deproteinized serum to which has been treated with an aqueous alkaline ferricyanide solution, whereby a purple solution is obtained which can be quantitated as to its uric acid content by standard colorimetric means.
  • Uric acid in abnormally high concentrations in the blood, tends to crystallize out in the body joints causing a very painful inflammatory condition known as gOutJHighairic acid blood levels are also known to be associated'with such conditions as uremia and those characterized-by whiteblood cells,
  • R4 0 B is selected from and CH R is selected from the group consisting of halogen, hydrogen, trifluoromethyl, nitro and amino; R is selected from the group consisting of and GEN; and R and R where taken together with their attached nitrogen atom form a radical selected from the group consisting of piperazinyl, lower alkyl substituted plperazinyh. pyrrolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl and lower'alkyl substituted piperidinyl;
  • R is selected from the group consisting of lower alkyl and hydrogen and water-soluble salts thereof, preferably in combination with a buffer, is added with an aqueous solution of ferric chloride to deproteinized serum which has been treated with an aqueous alkaline ferricyanide solution, whereby a purple solution is obtained which can be quantitated by standard colorimetric means.
  • benzodiazepine compounds of Formula I above which are particularly suitable as the color-forming reagent in the process of this invention include the following:
  • lower alkyl as used throughout this specification includes both straight and branched chain alkyl groups having from 1 to 7 carbon atoms such as methyl, ethyl, propyl, isopropyl and the like.
  • lower alkanoyloxy refers to both straight chain and branched chain aliphatic carboxylic acid moieties such as acetoxy, propionyloxy, butyryloxy and the like.
  • halo gen includes bromine, chlorine, fluorine and iodine.
  • water soluble acid addition salts of the compounds of Formula I above are also included within the purview of the present invention.
  • any conventional Water soluble acid addition salts of the compounds of Formula I above may be utilized in the process of this invention to quantitatively determine the iron content of aqueous solutions.
  • the acid addition salts which can be utilized in accordance with this invention, includes salts of compounds of the Formula I with organic or inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, acetic acid, formic acid, succinic acid, maleic acid, p-toluenesulfonic acid and the like.
  • the color differentiation with varying concentrations of ferrous ions produced by the compound of Formula I above is such that the concentration of ferrous ions pro prised by the instant diagnostic reagent compositions in situ can easily be determined by standard colorimetric instruments. Furthermore, the compounds of Formula I are not sensitive to extraneous sources and therefore are not affected by trace contaminants.
  • the method of this invention provides a simple colorimetric means for quantitatively determining the uric acid content of serum.
  • the uric acid content of serum is determined by treating a deproteinized sample of serum with an aqueous alkaline ferricyanide reagent and allowing the mixture to stand for a reasonable time, e.g., about 5 minutes, 'at ambient, i.e. room temperatures, thus forming in solution ferrocyanide ions and allantoin.
  • An aqueous solution containing ferric ions in the form of a water soluble ferric salt and a compound of Formula I is then added wherein ferricyanide ions and ferrous ions are produced.
  • the ferrous ions thus produced react with the compound of Formula I, preferably in the presence of a buffer, to produce a brillian deep purple color which is read colorimetrically thus affording a rapid, simple quantitative determination of the uric acid content of the sample which is ideally suited for routine diagnostic use.
  • the serum sample to betested is initially treated with a conventional deproteinizing agent.
  • Acidic deproteinizing agents such as, for example, trichloroacetic acid or tungstic acid, are preferred.
  • the specimen is well mixed with the deprotein izing agent in a ratio of 1:10 and centrifuged at high speed to obtain a clear supernate.
  • a 1.0 ml. aliquot of the clear supernate containing 0.1 ml. of specimen is treated at ambient temperature with about 2.0 ml. of an aqueous solution of an alkaline ferricyanide reagent and allowed to stand for about 5 minutes. The mixture is then treated with about 1.0 ml.
  • the solution containing ferricyanide ions can be made from any water soluble ferricyanide salt which does not otherwise interfere with the reaction such as, for example, potassium ferricyanide and sodium ferricyanide. Potassium ferricyanide is preferred in the practice of the present invention.
  • This reagent may be made in quantity if so desired and used as needed. The appropriate amount of potassium ferricyanide is dissolved in an aqueous alkaline medium such as, for example, a 2% sodium carbonate solution.
  • the quantity of ferricyanide salt utilized in preparing the reagent is variable. However, a sufficient quantity must be utilized to react with all the uric acid present in the specimen to furnish a positive indication of elevated uric acid blood levels when the diagonstic method of the present invention is being utilized as a diagnostic or a mass screening tool.
  • the reagent solution contains from about 0.18 ,umoles to about 1.5 11110165, most preferably from about 0.35 moles to about 0.7 ,umoles of ferricyanide salt. It is preferred that the ferricyanide reagent solution to be at a pH of from about 9 to about 11. This is readily accomplished by the addition thereto of a sufficient amount of an alkali metal hydroxide or carbonate. Most preferred for this purpose is sodium carbonate.
  • the quantity of ferric ions added to the sampleferricyanide ion mixture is again variable However, it is preferred to utilize a quantity of ferric ion slightly in excess of the molar quantity of ferricyanide ions added to the sample. The utilization of such an excess that there will be sufficient ferric ions present to react with the ferrocyanide ions generated by the initial reaction between the ferricyanide ions and the uric acid in the sample.
  • the ferric ions may be supplied as any water soluble ferric salt which does not interfere with the diagnostic determination such as, for example, ferric chloride, ferric nitrate, ferric sulfate and the like. Of these, ferric chloride is preferred.
  • the quantity of the compound of Formula I which is addedto the aqueous-reaction mixture is variable. In all instances, however, there must be a sufiicient quantity of the compound of Formula I present to react with all of the ferrous ions generated by the reaction between the ferric ions and the ferrocyanide ions. This quantity is most conveniently determined by equating the quantity of the compound of Formula I with that of the ferric ions to insure the stoichiometry of the chelation reaction.
  • test medium it is preferred to maintain the test medium at a pH of about 4.0 to about 5.0, preferably about 4.5. This can most easily be accomplished by adding suitable buffers to'the ferric ion reagent and the reagent containing the compound of Formula I. Buffering these reagents also makes them stable in aqueous solution when they are made up in quantity for large scale laboratory testing.
  • any recognized butler pair suitable for the maintenance of such a pH rangeas described above can be utilized.
  • a buffer pair a water soluble salt of acetic acid and acetic acid.
  • water soluble salts of acetic acid sodiu'rri acetate is preferred.
  • ammonium acetate, potassium acetate or other water soluble salt of acetic acid can be used, if desired.
  • the present invention contemplates the use of a sufiicient quantity of the acid component, e.g., acetic acid, to provide a final test sample having a pH in the range of from about 4.0 to about 5.0; preferably 4.5.
  • a sufiicient quantity of the acid component e.g., acetic acid
  • a final test sample having a pH in the range of from about 4.0 to about 5.0; preferably 4.5.
  • -By fiinal test sample is meant a solution containing the ferricyanide ions, the ferric ions and the benz'odiazepine color reagent.
  • compositions of the present invention may be utilized or handled as prepared aqueous stock solutions, aqueous concentrates or in a dry powder formLIn 'either the con- 'centrate or the power form, sufficient buifering agents are added to stabilize the compositions when the working dilutions are made and maintain the pH ofthe reaction mixture at between 4.0 and 5.0, preferably about 4.5.
  • the diagnostic compositions of the invention may be packaged in a dry state as a diagnostic kit or reagent system.
  • a reagent system the reagents may be packaged in amounts such that stock solutions can be formed therewith which are suitable for large scale testing either manually'o'r by continuous flow procedure as contemplated herein;
  • reagent systems maybe prepared which are suitable for single diagnostic determination.
  • a typical reagent system would also include uric acid from which -an aqueous solution would be prepared to be utilized as a standard for the colorimetric determinations.
  • the amount of reagents utilized in a given reagent system may be easily calculated in relation to the specimen being tested from the molar quantities given herein. These calculations are considered to be Well within the purview of a person skilled in the art.
  • a representative reagent system utilizing specific compounds would be as follows.
  • the above quantities represent sufficientfreag e nts for 1000 tests.
  • ThusfReagents A. andfiarehd sso vs 1n 2 liters of deionized water and 2 liters of a pH 4.5 acetate buffer, respectively.
  • Reagent B is dissolved in 1 liter of a 1 normal hydrochloric acid.
  • the uric acid standard may be prepared as a 100ml. stock solution as.described by Caraway in f sta'ndar d Methods of Clinical Chemistry (D. Seligson, eel), v01. Apps, ass-gagAsadsmis Press, NewYork (196 3). This stock: solution canthen be conveniently diluted to form standards for comparative purposes. It is also within the purview of the invention to prepare a reagent system for a single test utilizing quantities representing one thousandth of those given above. Further, the uric acid standard can be packaged in dry form or as an aqueous solution prepared
  • the addition of the compound of Formula I to the test system immediately produces the desired purple coloration.
  • the color deepens as the reaction proceeds to completion. Accordingly, in order to insure uniform coloring, the aqueous solution should be allowed to stand until its color appears to have become constant. *In general, it has been found that the full development of the purple color will occur over a period of from about 5 to 15 minutes after the addition of the compound of Formula I. In most cases 10 minutes is a sufficient period of time to allow for full color development.
  • the quantitation of the uric acid in the colored sample can be carried out by any conventional colorimetric method utilizing standard spectrophotometers such as Beckman Spectrophotometer, Coleman Spectrophotometer and the like.
  • the principle of the diagnostic method according to the present invention is based on a series of coupled reactions. Initially, uric acid present in the sample undergoing analysis reduces the ferricyanide ion in the added first reagent to ferrocyanide ions, which in turn form ferricyanide ions and ferrous ions with the addition of the second reagent which comprises a source of ferric ions such as, for example, ferric chloride, a buffer and a com pound of the Formula I. The ferrous ions thus generated react with the compound of the Formula I to produce a brilliant deep purple color. The purple color is thereafter colorimetrically measured and the uric acid content of the sample quantitatively determined.
  • the quantitative determination of the uric acid content in a specimen is carried out as follows: the absorbance of the purple color developed in the sample by the method of the present invention is measured against a reagent blank at 580 nm. utilizing a standard spectrophotometer such as, for example, a Beckman DBG Spectrophotometer, employing a cuvette with a 10 mm. light path.
  • the quantity of uric acid in the specimen is determined in the conventional manner from the absorbance of the specimen with reference to the absorbance of the color produced by a uric acid standard similarly treated.
  • the uric acid content of the specimen is calculated in accordance with the following formula:
  • Absorbance of specimen 'Absorbance of standard apparatus consist essentially of mixing specimens in continuous sequential flow with normal saline, dialyzing the mixture to produce an aqueous protein-free solution containing the uric acid, mixing the aqueous solution with an aqueous alkaline solution containing ferricyanide ions, mixing the aqueous solution with an aqueous solution of a ferric salt and a compound of the Formula I at a constant pH of from about 4.5 to about 5.5 and passing the resulting solution through an apparatus which quantitatively determines the glucose content thereof photometrically.
  • FIG. 1 is a schematic flow diagram illustrating a continuous flow automated system for analyzing uric acid in biological fluids utilizing the diagnostic composition of the present invention.
  • FIG. 2 is a recording of the photometric response obtained when utilizing the automated system of FIG. 1.
  • FIG. 3 is a plot in terms of absorbance of the photometric response illustrated in FIG. 2.
  • FIG. 1 a continuous flow automated testing system is shown schematically wherein a specimen sample to be tested, i.e., serum, is drawn up in sequence from separate sample cups in the sample plate which rotates at a constant speed to provide the system with 20-60 specimen samples with a 2:1 wash ratio per hour.
  • a sample, so drawn, is mixed in flow with normal saline and passed through a glass mixing coil of conventional design. After the mixture has passed through the mixing coil, it is next pumped through a dialyzer module that is provided with a cellophane membrane or the like through which the uric acid passes in aqueous solution by dialysis.
  • the dialyzer module is maintained at a constant temperature of 37 C. The residual, non-diffusable portion of the sample is discarded.
  • aqueous uric acid solution passes through the dialyzer module membrane it is admixed with an aqueous alkaline solution containing ferricyanide ions, preferably in the form of potassium ferricyanide which react to form allantoin and ferrocyanide ions.
  • the aqueous stream is then mixed in continuous flow with an aqueous solution containing ferric ions, preferably in the form of ferric chloride, and a reagent stream comprising the 5-(2-pyridyl) 2H 1,4- benzodiazepine color reagent of Formula I.
  • the color reagent preferably 7-bromo 1,3 dihydro-1-(3-dimethylaminopropyl) 5 (Z-pyridyl) 2H 1,4 benzodiazepin-Z-one, is maintained at a pH of about 4.5 to 5.5, preferably at about 5.0.
  • the mixture is then passed through a second mixing coil. As the mixture is in transit through this coil, the ferric ions and ferrocyanide ions react to form ferricyanide ions and ferrous ions which in turn react with the benzodiazepine color reagent to form a brilliant purple coloration. Photometric measurements are then performed at 580 nm. in a mm.
  • flowcell colorimeter i.e., the absorbance of the solution to be tested in measured at 580 nm. in a flow-cell colorimeter using a 580 nm. filter.
  • the results of the colormetric readings are recorded on a conventional recording mechanism.
  • the continuous flow system illustrated in FIG. 1 aspirates at a rate of to 60 specimens/hour.
  • the rate of flow in ml./min. of the materials entering the system according to a preferred technique is illustrated in FIG. 1.
  • the materials entering the system are pumped into it by any suitable pumping means adjusted to maintain the rate of flow illustrated in FIG. 1.
  • the mechanism for the system of the present invention can be conveniently provided by a manifold assembly prepared in accordance with the system illustrated in FIG. 1 adaptable to the Technicon Autoanalyzer.
  • FIG. 2 the absorbance of solutions containing graduated amounts of uric acid, e.g., 2 rug/100 ml., 4 mg./ 100 ml., 8 mg./ 100 ml., etc. are plotted as a graph against concentration.
  • FIG. 3 the photometric response of solutions containing dilferent concentrations of uric acid is demonstrated.
  • the drawing illustrates four separate experiments, each of which represents passage through the automated system of FIG. 1 of a sequence of at least three solutions having uric acid concentrations in the order of low to high to low, such as, for example, 2 mg. per
  • the reagents utilized in connection with the automated procedure of uric acid determination comprise aqueous solutions of a ferricyanide reagent, a ferric ion containing reagent and the buffered color forming reagent.
  • the ferricyanide reagent comprises sufiicient ferricyanide to react with all the uric acid in the sample, for example, 0.115 g. potassium ferricyanide dissolved in 1 liter of 2.0% sodium carbonate and 0.9% sodium chloride.
  • the ferric ion containing solutions comprises sufiicient ferric ions to react with all the ferrocyanide ions formed in the initial reaction, for example, 0.27 g. ferric chloride dissolved in 1 liter of 1 N hydrochloric acid.
  • the colorforming reagent comprises sufiicient color-forming compound to react with the ferrous in the ions formed by the reaction of the ferric ions and the ferrocyanide ions, for example, 1.88 g; of a compound of Formula I, 82.0 g. of anhydrous sodium acetate and approximately 40.0 ml. of glacial acetic acid in a liter of distilled water. The pH of the solution is maintained between about 4.4 and 4.6.
  • iron-free distilled water is pumped through the system for 10 minutes.
  • the system is then switched to reagent and the pumping is continued until a steady base line is obtained on the recorder chart.
  • the base line is set to -0.0lA percent transmission).
  • the standards in the sample tray are aspirated at a rate of 20 to 60 (2:1 wash ratio) samples per hour.
  • the specimens to be analyzed are then sampled, with a standard uric acid specimen which is aspirated intermittently to insure qualitative control.
  • the uric acid content of each specimen is determined by reference to a calibration curve prepared by plotting the corrected absorbances of the uric acid standards against concentrations in mg./ ml.
  • Table I sets forth a comparison of results obtained when 10 randomly selected plasma specimens were analyzed utilizing the automated and manual uric acid procedures of the present invention and a prior art method of determining uric acid utilizing uric acid oxidase.
  • the uric acid oxidase method utilized was that described by Remp in Standard Methods of Clinical Chemistry (R. P. MacDonald, ed.,) vol. 6, pp. 1-12, Academic Press, New York, New York 15 75.
  • Serum Pool #1 6.4 plus Serum Pool #2, 5,5 j 6. 6. 0 100.0 Serum Pool #1, 6.4 plus Serum Pool #3, 6.3 6. 4 6. 5 101. 5 Serum Pool #1, 6.4 plus Serum Pool #4, 7.4 6.9 7.1 Y 102. 8 Serum Pool #2, 5.5 plus Serum Pool #3, 6.3-. 5.9 6.0 101. 7 Serum Pool #2, 5.5 plus Serum Pool #4, 7 .4 0. 5 6. 6 101. 5 Serum Pool #3, 6.3 plus Serum Pool #4, 7.4 6. 8 6. 7 98. 5
  • Serum Pool #1, 6.4 plus Standard 2.0 4. 2 "4.1 07.? Serum Pool #1, 6. 4 plus Standard, 4.0 5. 2 5. 1 98. 0 Serum Pool #1, 6.4. plus Standard, 8.0 7.2 7.1 98.6 Serum Pool #1, 6.4. plus Standard, 12.0.. 9. 2 9. 5 103.2 Serum Pool #1, 6.4 plus Standard, 16.0 11.2 11.2 100.0 Serum Pool #1, 6.4. plus water 3. 2 3. 1 96.8 Serum Pool #1, 6.4. plus LiCOa solution 3.2 3.1 96. 8
  • the oil was next dissolved in .100 ml. of ethyl 40 treated in the same manner against concentration or by acetate and filtered over 100 g. of activated neutral alu-' 1 the Beer-Lambert formula. Utilizing 10 mg. uric acid/100 mina (Grade I); Using ethyl acetate as the eluant, 7- ml. as a standard, the concentration of the specimen was bromo-1,3-dihydro 1 (3-dirnethylaminopropyl). 5 (2- calculated according to the formula: pyridyl)-2H-1,4-benzodiazepin-2-one was recovered from the column. 7 A580 um.
  • R is 2-pyridyl; R is selected from the group consisting of lower alkyl, hydrogen,
  • R is lower alkyl; and R is selected from the group consisting of lower alkyl and hydrogen, and water soluble acid addition salts thereof;
  • color-forming benzodiazepine compound is selected from the group consisting of 7-bromo-1,3-dihydro-l-(3-dimethylaminopfopyl) 5 (Z-pyridyl)-2H-l,4-benzodiazepin-Z-one and water soluble acid addition salts thereof.
  • a method for the quantitative analysis of the uric acid content of blood serum consisting esesntially of providing in continuous flow the sequential steps comprising:
  • R is selected from the group consisting of lower alkyl; hydrogen,
  • R and R where taken together with their attached nitrogen atom, form a radical selected from the group consisting of piperazinyl, lower alkyl substituted piperazinyl, pyrolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl, and lower alkyl substituted piperidinyl;
  • R is lower alkyl; and
  • R is selected from the group consisting of lower alkyl and hydrogen thereof and water soluble acid addition salts thereof thereby forming a colored so lution;
  • said color-forming benzodiazepine compound is selected from the group consisting of 7-bron1o-1,3-dihydro-l-(3-dimethylaminopropyl)-5-(2-pyridyl) 2H 1,4 benzodiazepin- 2-one and water-soluble acid addition salts thereof.
  • a reagent system for the determination of the uric acid content of blood serum samples consisting essentially of:
  • a third container containing at least an equimolar amount of a color-forming compound selected from the group of compounds represented by the formula wherein A is selected from the group consisting of B is selected from the group of and CH R is selected from the group consisting of halogen, hydrogen, trifluoromethyl, nitro and amino; R is selected from the group consisting of H -R7-Ru hydrogen, lower alkyl and R5 -Cu'lIznN 12 is an integer from 2 to 7; R is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower alkoxy and lower alkanoyloxy; R is Z-pyridyl;
  • R is selected from the group consisting of lower alkyl, hydrogen,
  • R and R where taken together with their attached nitrogen atom, form a radical selected from the group consisting of piperazinyl, lower alkyl substituted piperazinyl, pyrrolidinyl, lower alkyl substituted pyrrolidinyl, piperidinyl and lower alkyl substituted piperidinyl; R is lower alkyl; and R is selected from the group consisting of lower alkyl and hydrogen, and water soluble acid addition salts thereof based on the amount of said water-soluble ferric iron salt present in reagent (b); and
  • a fourth container containing, as a standard, a substance selected from the group consisting of uric acid and aqueous solutions thereof.
  • a reagent system in accordance with claim 10 wherein said water-soluble ferricyanide salt in said first container is potassium ferricyanide, salt alkalinizing substance is sodium carbonate, said water-soluble ferric iron salt in said second container is ferric chloride, said colorforming compound in said third container is selected from the group consisting of 7-bromo-1,3-dihydro-1-(3-dimethylaminopropyl) 5 (2-pyridyl)-2H-1,4-benzodiazepin-2- one and water-soluble acid addition salts thereof and said first container contains from about 0.35 to about 0.7a moles of potassium ferricyanide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US00214770A 1972-01-03 1972-01-03 Methods and compositions for the determination of uric acid in blood Expired - Lifetime US3733177A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21477072A 1972-01-03 1972-01-03

Publications (1)

Publication Number Publication Date
US3733177A true US3733177A (en) 1973-05-15

Family

ID=22800355

Family Applications (1)

Application Number Title Priority Date Filing Date
US00214770A Expired - Lifetime US3733177A (en) 1972-01-03 1972-01-03 Methods and compositions for the determination of uric acid in blood

Country Status (5)

Country Link
US (1) US3733177A (cg-RX-API-DMAC7.html)
JP (1) JPS4875096A (cg-RX-API-DMAC7.html)
DE (1) DE2263538A1 (cg-RX-API-DMAC7.html)
FR (1) FR2167617A5 (cg-RX-API-DMAC7.html)
NL (1) NL7300069A (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4095948A (en) * 1973-10-19 1978-06-20 Hoffmann-La Roche Inc. Determination of uric acid
US5695719A (en) * 1993-04-29 1997-12-09 Danfoss A/S Device for analyzing a fluid medium
US5939330A (en) * 1996-08-02 1999-08-17 Peterson; Roger Method and apparatus for gathering and preparing liquid samples for analysis
CN113218896A (zh) * 2021-04-22 2021-08-06 杭州电子科技大学 用于判断食品受虫害侵染程度的分析方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4095948A (en) * 1973-10-19 1978-06-20 Hoffmann-La Roche Inc. Determination of uric acid
US5695719A (en) * 1993-04-29 1997-12-09 Danfoss A/S Device for analyzing a fluid medium
US5939330A (en) * 1996-08-02 1999-08-17 Peterson; Roger Method and apparatus for gathering and preparing liquid samples for analysis
CN113218896A (zh) * 2021-04-22 2021-08-06 杭州电子科技大学 用于判断食品受虫害侵染程度的分析方法

Also Published As

Publication number Publication date
JPS4875096A (cg-RX-API-DMAC7.html) 1973-10-09
DE2263538A1 (de) 1973-07-19
FR2167617A5 (cg-RX-API-DMAC7.html) 1973-08-24
NL7300069A (cg-RX-API-DMAC7.html) 1973-07-05

Similar Documents

Publication Publication Date Title
US3653841A (en) Methods and compositions for determining glucose in blood
Denckla et al. The determination of tryptophan in plasma, liver, and urine
Koepsell et al. Microdetermination of pyruvic and α-ketoglutaric acids
Masaru et al. A direct method for the estimation of ornithine carbamoyltransferase activity in serum
US3630847A (en) Diagnostic agent for use in the determination of hydroperoxides and of peroxidate-active substances
US4308027A (en) Method and composition for direct determination of iron in blood serum
Lindstedt et al. Analytical and clinical evaluation of a radioimmunoassay for gastrin.
CA1144461A (en) Chromogenic detection of endotoxin in human serum and plasma
US3733177A (en) Methods and compositions for the determination of uric acid in blood
US3506403A (en) Colorimetric method for determining iron in fluids
CA2554899C (en) Method and kit for the measurement of neutrophil cell activation
JPH0630633B2 (ja) アレルギーの検出法並びに該方法に好適な試薬及び装置、及びアレルギー用薬及び抗炎症剤の測定法
US3667915A (en) Colorimetric methods and compositions for determining iron in blood
US3506404A (en) Colorimetric method for determining iron in blood
US4105408A (en) Urea assay
Rice Improved biuret procedure for routine determination of urinary total proteins in clinical proteinuria
RU2122740C1 (ru) Способ определения мочевины в биологических жидкостях и набор реактивов для его осуществления
US3822115A (en) Method and reagent for uric acid determination
US4040787A (en) Urea determination of biological fluids using diacetylmonoxime reaction
DE4215275A1 (de) Mittel und Verfahren zur Behandlung von Körperflüssigkeiten bei der Bestimmung von Neopterin
US3649198A (en) Diagnostic method for the determination of uric acid in blood
US4211531A (en) Colorimetric cholesterol assay
SU416969A3 (cg-RX-API-DMAC7.html)
Asp Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent
SU1367838A3 (ru) Способ определени антистрептолизин- @ -овых антител в крови (его варианты)